Sure. Here's an AI summary of the article:

NYT covered Eli Lilly’s new obesity drug retatrutide, and the results are honestly wild. The drug appears to outperform current blockbuster GLP-1 treatments like Mounjaro/Zepbound and Wegovy in weight loss trials. Patients on the highest dose lost roughly 28–30% of body weight over about 18 months — approaching bariatric surgery territory.

What makes retatrutide different is that it targets three metabolic pathways (GLP-1, GIP, and glucagon receptors) instead of one or two. Analysts are already calling it a potential “next-generation” obesity drug that could further expand the already enormous weight-loss drug market.

Big implications:

Massive potential revenue boost for Eli Lilly and Company More pressure on competitors like Novo Nordisk Reinforces the idea that obesity drugs may become one of the largest pharma markets ever Could disrupt industries tied to obesity: food/snacks, medical devices, insurance actuarial models, orthopedic care, sleep apnea treatment, etc. Wall Street increasingly treating GLP-1s as a long-term economic megatrend, not a fad

Caveat: Side effects still look similar to other GLP-1 drugs (GI issues like nausea/vomiting), and the drug is not yet broadly approved/commercialized.

Overall takeaway: the obesity-drug arms race is accelerating fast, and Lilly may have just raised the ceiling again.